NFKB1 and breast cancer: Considering that the ERK1/2 pathway may crosstalk with other signaling pathways, and that reports are found on both ERK 1/2 and the NF-κB being involved in cDDP-acquired resistance in BC cells [51, 52], we propose that the constitutive activation of NF-κB and of ERK1/2 pathways is modified by exposure of S cells to cDDP, with a slightly increase of NF-κB as well as a downregulation of ERK1/2 pathways that might be associated with TNBC survival and its more aggressive characteristics.